Glutathione
Also sold as: Reduced glutathione · GSH · Oral glutathione
An endogenous antioxidant tripeptide sold in ordinary and liposomal oral products. Increasing blood glutathione is a biomarker result, not proof of longer life, anxiety relief or disease treatment.
Longevity Energy
Community
Not enough ratings yet: 0 of 10
Scores appear after 10 ratings, so that one or two reports can't dominate. Tried it? Your rating counts.
Research
- Energy: Redox associations and glutathione-rich-food crossover studies do not establish an ergogenic effect of isolated oral glutathione.
- Longevity: No established lifespan or hard aging-outcome benefit from oral glutathione. GlyNAC precursor trials are a separate intervention and cannot supply that claim.
REALITY CHECK // The oral-GSH question is not settled by either calling it completely unabsorbable or labeling it a master antioxidant. Some small chronic studies raise body stores, while clinical benefits remain uncertain and precursor GlyNAC trials are a different intervention. IV skin-lightening and inhalation carry route-specific risks that oral-capsule studies cannot dismiss.
Levels: how we grade evidence. Grey = evidence of no benefit; amber = evidence it makes this goal worse.
Ratings are self-reported by a self-selected group of users: how it felt, not proof that it works.
Check your bottle
Compare what your label says with what was used in trials. This is a trial range, not a personal prescription.
Enter the amount from your label to see the result.
How it was studied
UPPER LIMIT // No EFSA or NIH numerical UL is established in this dossier. Oral 250-1,000 mg/day trial tolerability does not establish a universal long-term ceiling, and it does not apply to IV or inhaled products.
Summary
A small six-month oral trial found higher glutathione stores, but absorption findings vary with preparation and acute versus chronic testing. Liposomal studies mainly support biomarker or availability signals; clinical superiority remains unproved. GlyNAC, skin-lightening studies and Parkinson trials must be kept separate from a general oral-GSH health claim.
Mechanism
Glutathione participates in cellular redox reactions and peroxide handling and is synthesized from amino-acid precursors. NAC plus glycine supplies substrates for endogenous synthesis, while swallowed glutathione has a different absorption and metabolism question. Selenium supports glutathione-peroxidase function; vitamin C participates in antioxidant recycling.
Typical studied dose
Oral GSH studies in the dossier used 250-1,000 mg/day for up to six months. The skin study used 500 mg/day for a short course; skin trials generally ran 4-12 weeks. GlyNAC studies in older adults ran 12-24 weeks but cannot be expressed as a single interchangeable GSH milligram dose. Intranasal and IV trials are separate medical routes.
Upper limit
No EFSA or NIH numerical UL is established in this dossier. Oral 250-1,000 mg/day trial tolerability does not establish a universal long-term ceiling, and it does not apply to IV or inhaled products.
Popular stacks with Glutathione
Not enough stack data yet. A combination with Glutathione appears here once 5 people rate the same set.
Forms and label traps
| Form on label | Active content | Studied range / day | Absorption & GI tolerance | Verdict |
|---|---|---|---|---|
| Oral reduced glutathione / pure GSH Best for: Matching actual reduced-GSH mass to the oral trial range. |
Extract weight · ~100% marker | 250–1000 mg | Acute availability and chronic body-store findings differ; clinical outcome benefit remains uncertain. Generally tolerated in the cited range; headache or nausea can occur. |
Studied standard [REFERENCE // STUDIED_FORM] 100% describes pure GSH mass, not a mineral conversion or guarantee of whole-molecule absorption. The range concerns biomarkers and tolerability, not a proven longevity target. |
| Liposomal glutathione with declared actual GSH content Best for: Checking whether the back label declares actual GSH separately from total liposomal blend. |
Unstandardized: active content unknown | no comparable trial range | Small human and cellular studies suggest increased availability; no large clinical-outcome superiority trial establishes value. Generally tolerated in small studies; product quality and price vary. |
Caution [CAUTION // CHECK_BASIS] The dossier does not supply a reliable form-specific dose interval or fixed GSH percentage of the liposomal blend. No assumed 100% active blend or conversion is used. |
| GlyNAC: glycine plus N-acetylcysteine, not ready-made GSH Best for: Distinguishing a two-ingredient precursor protocol from glutathione capsules. |
Unstandardized: active content unknown | no comparable trial range | Provides substrates for endogenous synthesis; promising selected older/HIV populations differ from oral-GSH trials. NAC can cause gastrointestinal intolerance; anxiety/sleep complaints are anecdotal. |
Caution [CAUTION // CHECK_BASIS] Do not add glycine and NAC mass into a generic GSH dose. Some catalog entries lack titles, leaving the precursor evidence in review. |
| IV, intranasal or nebulized glutathione Best for: Recognizing routes unsuitable for consumer dose matching. |
Unstandardized: active content unknown | no comparable trial range | Different routes with medical or research settings; bypassing the gut does not prove clinical benefit. IV systemic/infection hazards; inhaled bronchoconstriction in asthma. |
Avoid / not comparable [AVOID // UNSUITABLE] No self-treatment dose target. The intranasal Parkinson trial did not show significant superiority over placebo; cosmetic IV safety is a distinct concern. |
Common label traps
- TRAP_01 // All swallowed GSH is useless
A small chronic RCT found higher body stores, including about 30-35% higher blood GSH with 1,000 mg/day after six months. That does not establish clinical benefit or settle every acute absorption study. - TRAP_02 // Liposomal means proven clinical superiority
Availability and small biomarker studies cannot establish better longevity, immunity or disease outcomes than ordinary GSH. - TRAP_03 // Permanent skin whitening or generic detox
Short skin trials suggest small changes, with uncertain durability after stopping. No large hard-outcome evidence validates a general detox claim. - TRAP_04 // GlyNAC proves oral GSH slows aging
Glycine plus NAC is a different intervention. Older-adult precursor trials cannot be assigned to GSH capsules or to a young healthy population. - TRAP_05 // IV is the best and safest upgrade
Bypassing the gut does not validate benefit. Cosmetic infusions have serious reported risks, and nebulized GSH can constrict airways in asthma.
Other outcomes studied
Outside the five leaderboard goals. Same evidence levels as above.
- BODY GLUTATHIONE STORES Limited · benefit
In a 54-person chronic RCT, 1,000 mg/day increased blood GSH by about 30-35% after six months; the dossier reports no significant effect at 250 mg. Acute absorption findings differ. This is a biomarker, not an anxiety endpoint.
PMID 24791752 PMID 25792077 PMID 41897500 - LIPOSOMAL AVAILABILITY Limited · benefit
A 12-person nonrandomized study and later cellular/human work suggest greater availability. Preclinical formulation evidence and small human findings do not prove hard clinical superiority.
PMID 28853742 PMID 41559937 PMID 30843439 - GLYNAC PRECURSORS / OLDER ADULTS Limited · benefit
The dossier reports improvements in GSH stores, oxidative-stress and physical/metabolic markers with glycine plus NAC, including selected older-adult studies. This is a different intervention, with incomplete bibliographic metadata for several cited entries; lifespan extension is unproved.
PMID 35975308 PMID 33783984 PMID 33007928 PMID 34587244 - SKIN PIGMENTATION Limited · benefit
Small short-term trials and reviews suggest modest melanin-index changes. Lasting lightening after stopping is not established, and combined topical/oral products limit attribution.
PMID 20524875 PMID 33871071 PMID 30895708 PMID 39444151 - PARKINSON DISEASE Limited · no benefit
The intranasal phase IIb trial found no significant UPDRS advantage over placebo. Earlier pilot IV/intranasal findings do not establish disease modification.
PMID 28436395 PMID 26230671 PMID 19230029 - FATTY LIVER DISEASE No established evidence
A GST gene-polymorphism review and preclinical redox work do not establish efficacy of oral GSH for MASLD/NAFLD. Unestablished benefit is not a definitive negative supplement RCT.
PMID 36197156 PMID 23534396 - EXERCISE / INDIRECT REDOX EVIDENCE No established evidence
Erythrocyte-redox physiology and a glutathione-rich fruit intervention do not isolate a performance benefit from oral GSH. Correlation or a food response cannot supply the isolated-supplement claim.
PMID 40719977 PMID 38502949
Reader questions
Does oral glutathione actually get absorbed?
A chronic trial found increased body stores, whereas acute exposure studies are not consistently positive. Meaningful availability and a health benefit are separate questions; neither complete uselessness nor universal efficacy follows.
Is liposomal GSH better than plain GSH or NAC?
Small availability studies favor some liposomal formulations, but no large clinical-outcome comparison settles value. NAC, especially with glycine, is a precursor approach and cannot be compared by adding milligram totals.
Are IV glutathione infusions worth the risk?
A consumer wellness or cosmetic rationale does not establish benefit. Reviews describe severe reactions and organ/infection concerns; IV treatment belongs in a medical indication and supervised setting.
Will it permanently lighten skin?
Short studies show modest melanin-index changes in selected populations. Durability after stopping and long-term safety are insufficiently documented; IV use is not justified by oral cosmetic data.
Can it cause anxiety or breathing symptoms?
Anxiety and sleep complaints with GSH/NAC are anecdotal and do not prove glutamate causation. Nebulized GSH has a different, direct bronchoconstriction signal in asthma. New breathing difficulty needs medical assessment.
Does it help recovery after COVID or detoxification?
The supplied clinical outcome set does not establish either claim. A change in antioxidant markers alone is not proof of faster recovery or removal of unspecified toxins.
Stack interactions
- Caution Psychiatric medicines and high-dose NAC stacks [CAUTION // CLINICAL_REVIEW]
Anxiety, headache and sleep complaints are user reports; a controlled causal drug interaction has not been established. Review symptoms and the complete regimen rather than assuming more antioxidant exposure is better. - Caution Glucose-lowering treatment / GlyNAC [CAUTION // CLINICAL_REVIEW]
A GlyNAC older-adult trial in the dossier reports improved insulin sensitivity. Potential additive effects are a precaution; this is neither a drug-interaction RCT nor proof for ready-made oral GSH.
PMID 35975308 - Danger Chemotherapy or transplant immunosuppression [CAUTION // CLINICAL_REVIEW]
Potential antioxidant interference is mechanistic and treatment dependent. Use requires the treating specialist, not an automatic claim that every combination is harmful. - Caution Vitamin C, selenium and other antioxidant ingredients [CAUTION // CLINICAL_REVIEW]
These participate in recycling or enzyme function. Mechanistic complementarity does not establish improved clinical outcomes from an escalating multicomponent stack.
Red flags: interactions and who should avoid it
Interactions
Psychiatric-treatment cautions and reports of anxiety with GSH/NAC are anecdotal or mechanistic, not established interaction trials. GlyNAC-associated insulin-sensitivity findings suggest a precaution with glucose-lowering therapy, but are not proof of an oral-GSH drug interaction. Oncology or transplant/immunosuppression teams should decide on use because antioxidant-treatment interference is mechanistically possible.
Avoid or ask a doctor first if
Asthma is a particular contraindication to nebulized/inhaled GSH because bronchoconstriction was observed in a clinical trial. Avoid cosmetic IV/injection use: reviews discuss severe skin reactions, kidney/liver dysfunction and infection risks. Pregnancy and breastfeeding lack supplemental-dose safety data. Review active cancer treatment, transplantation and treated neurological/psychiatric conditions with the specialist. Oral nausea or headache can occur; new breathing symptoms need medical assessment.
Sources (PubMed, 22)
- Randomized controlled trial of oral glutathione supplementation on body stores of glutathione.
PMID 24791752 · 2015 · randomized controlled trialSmall six-month oral RCT: increased body GSH stores, especially with the 1,000 mg dose; biomarker result.
- Commentary to \"Randomized controlled trial of oral glutathione supplementation on body stores of glutathione\".
PMID 25792077 · 2015 · commentaryCommentary on interpretation of the oral-store RCT and its availability question, not an independent efficacy trial.
- A Targeted Metabolomic Assessment of Oral Glutathione Bioavailability and Safety in Humans: A Randomized Crossover Clinical Trial.
PMID 41897500 · 2026 · randomized controlled trialHuman crossover study of oral-GSH availability/safety; detailed efficacy outcomes beyond the dossier were not inferred.
- Oral supplementation with liposomal glutathione elevates body stores of glutathione and markers of immune function.
PMID 28853742 · 2018 · clinical report / other studySmall nonrandomized liposomal-GSH study with body-store and immune-marker changes.
- Liposomal glutathione outperforms plain glutathione in uptake, cell regeneration and systemic availability: evidence from cellular and human models.
PMID 41559937 · 2026 · randomized controlled trialCellular and human availability comparison; not a large hard-clinical-outcome superiority trial.
- Design of novel proliposome formulation for antioxidant peptide, glutathione with enhanced oral bioavailability and stability.
PMID 30843439 · 2019 · animal studyPreclinical proliposome formulation/availability study; no human clinical-outcome claim.
- Supplementing Glycine and N-acetylcysteine (GlyNAC) in Aging HIV Patients Improves Oxidative Stress, Mitochondrial Dysfunction, Inflammation, Endothelial Dysfunction, Insulin Resistance, Genotoxicity, Strength, and Cognition: Results of an Open-Label Clinical Trial.
PMID 33007928 · 2020 · clinical report / other studyOpen-label GlyNAC precursor study in aging HIV patients; a different intervention and population.
- Glutathione as an oral whitening agent: a randomized, double-blind, placebo-controlled study.
PMID 20524875 · 2012 · randomized controlled trialSmall short-term oral 500 mg/day skin-pigmentation trial.
- Combination of topical and oral glutathione as a skin-whitening agent: a double-blind randomized controlled clinical trial.
PMID 33871071 · 2021 · randomized controlled trialCombined topical/oral skin-lightening trial; cannot assign the entire effect to oral GSH.
- The clinical effect of glutathione on skin color and other related skin conditions: A systematic review.
PMID 30895708 · 2019 · systematic review / meta-analysisSystematic review: weak/short-term skin findings with uncertain durability.
- Glutathione as a skin-lightening agent and in melasma: a systematic review.
PMID 39444151 · 2025 · systematic review / meta-analysisUpdated skin-lightening/melasma review; limited evidence and route distinctions matter.
- The Glutathione Derivative, GSH Monoethyl Ester, May Effectively Whiten Skin but GSH Does Not.
PMID 27128906 · 2016 · in vitro studyIn vitro derivative findings cannot establish clinical skin efficacy of ordinary GSH.
- Exploring the Safety and Efficacy of Glutathione Supplementation for Skin Lightening: A Narrative Review.
PMID 40013212 · 2025 · narrative reviewNarrative skin-supplementation safety/efficacy review, including nonoral concerns.
- Glutathione as a skin whitening agent: Facts, myths, evidence and controversies.
PMID 27088927 · 2016 · narrative reviewReview of skin-whitening claims and IV route risks.
- Phase IIb Study of Intranasal Glutathione in Parkinson's Disease.
PMID 28436395 · 2017 · randomized controlled trialIntranasal phase IIb Parkinson trial: no significant UPDRS advantage over placebo.
- A randomized, double-blind phase I/IIa study of intranasal glutathione in Parkinson's disease.
PMID 26230671 · 2015 · randomized controlled trialEarlier intranasal Parkinson pilot; does not establish disease modification.
- Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease.
PMID 19230029 · 2009 · randomized controlled trialSmall IV Parkinson pilot; medical route and uncertain efficacy.
- Association of glutathione S-transferases (GSTT1, GSTM1 and GSTP1) genes polymorphisms with nonalcoholic fatty liver disease susceptibility: A PRISMA-compliant systematic review and meta-analysis.
PMID 36197156 · 2022 · systematic review / meta-analysisGST gene-polymorphism/NAFLD susceptibility synthesis, not an oral-GSH intervention trial.
- Impaired mitochondrial fatty acid oxidation and insulin resistance in aging: novel protective role of glutathione.
PMID 23534396 · 2013 · animal studyPreclinical aging/redox/insulin-resistance mechanism; not proof of human liver benefit.
- Erythrocyte Glycolytic and Redox Metabolism Affects Muscle Oxygenation and Exercise Performance: A Randomized Double-Blind Crossover Study in Men.
PMID 40719977 · 2025 · randomized controlled trialErythrocyte-redox/exercise crossover physiology; no isolated oral-GSH efficacy inference.
- Juçara (Euterpe edulis Martius) improves time-to-exhaustion cycling performance and increased reduced glutathione: a randomized, placebo-controlled, crossover, and triple-blind study.
PMID 38502949 · 2024 · randomized controlled trialFruit intervention and exercise/GSH changes; does not isolate a GSH-capsule effect.
- Nebulized glutathione induces bronchoconstriction in patients with mild asthma.
PMID 9279219 · 1997 · randomized controlled trialNebulized GSH caused bronchoconstriction in people with mild asthma.
Community comments
No approved comments yet. Comments are held for moderation.